The efficacy of Zafirlukast as a SARS-CoV-2 helicase inhibitor in adult patients with moderate COVID-19 Pneumonia (pilot randomized clinical trial)

Mohammed Al Ghobain(King Saud bin Abdulaziz University for Health Sciences), Majed Al Jeraisy(King Saud bin Abdulaziz University for Health Sciences), Amer Hayat Khan(Universiti Sains Malaysia), Fatimah Rebh(Prince Mohammed bin Abdulaziz Hospital), Nimer Mehyar(King Saud bin Abdulaziz University for Health Sciences), Abdullah Mashhour(King Saud bin Abdulaziz University for Health Sciences), A.S. Alaskar(King Saud bin Abdulaziz University for Health Sciences), Mohamed Boudjelal(King Saud bin Abdulaziz University for Health Sciences), Imadul Islam(King Saud bin Abdulaziz University for Health Sciences), Al Saad(King Saud bin Abdulaziz University for Health Sciences), Y. Alobaida
Journal of Infection and Public Health
November 16, 2022
10.1016/j.jiph.2022.11.016
Cited by 6

Related Papers

Treatment of Middle East Respiratory Syndrome with a combination of lopinavir-ritonavir and interferon-β1b (MIRACLE trial): study protocol for a randomized controlled trial
|Trials|2018|261
A Standardized Dataset of a Spontaneous Adverse Event Reporting System
|Healthcare|2022|138
Quantifying Uncertainty in Analytical Measurements
|Journal of Bangladesh Academy of Sciences|2018|133
Treatment of Middle East respiratory syndrome with a combination of lopinavir/ritonavir and interferon-β1b (MIRACLE trial): statistical analysis plan for a recursive two-stage group sequential randomized controlled trial
|Trials|2020|132
Prevalence and predictors of depression among hemodialysis patients: a prospective follow-up study
|BMC Public Health|2019|115